

Title (en)

FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE AND ALBUMIN

Title (de)

PARENTERAL ANZUWENDENDE ARZNEIZUSAMMENSETZUNGEN ENTHALTEND ESTRAMUSTINPHOSPHAT UND ALBUMIN

Title (fr)

FORMULATIONS DE PHOSPHATE D'ESTRAMUSTINE ET D'ALBUMINE A UTILISATION PAR VOIE PARENTERALE

Publication

EP 1206266 A2 20020522 (EN)

Application

EP 00949471 A 20000803

Priority

- EP 0007678 W 20000803
- GB 9918779 A 19990809
- IT MI991998 A 19990927

Abstract (en)

[origin: WO0110446A2] A pharmaceutical formulation which comprises a parenterally acceptable carrier or a diluent and estramustine phosphate in admixture with human albumin, wherein the weight ratio of estramustine phosphate to human albumin is from about 1:5 to about 1:0.3. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables estramustine phosphate to be administered with no side effects at the site of injection.

IPC 1-7

A61K 31/565; A61K 31/66; A61K 9/08; A61K 47/42; A61P 35/00

IPC 8 full level

A61K 9/08 (2006.01); **A61K 9/19** (2006.01); **A61K 31/335** (2006.01); **A61K 31/40** (2006.01); **A61K 31/47** (2006.01); **A61K 31/475** (2006.01); **A61K 31/555** (2006.01); **A61K 31/565** (2006.01); **A61K 31/66** (2006.01); **A61K 31/661** (2006.01); **A61K 31/70** (2006.01); **A61K 33/00** (2006.01); **A61K 38/38** (2006.01); **A61K 45/00** (2006.01); **A61K 47/42** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP KR)

A61K 9/0019 (2013.01 - EP); **A61K 31/335** (2013.01 - EP); **A61K 31/40** (2013.01 - EP); **A61K 31/47** (2013.01 - EP); **A61K 31/475** (2013.01 - EP); **A61K 31/555** (2013.01 - EP); **A61K 31/565** (2013.01 - EP); **A61K 31/66** (2013.01 - EP); **A61K 31/661** (2013.01 - EP); **A61K 31/70** (2013.01 - EP); **A61K 33/00** (2013.01 - EP); **A61K 35/16** (2013.01 - KR); **A61K 38/38** (2013.01 - EP); **A61K 47/42** (2013.01 - EP); **A61P 35/00** (2017.12 - EP)

C-Set (source: EP)

1. **A61K 38/38 + A61K 33/00 + A61K 31/66 + A61K 31/565**
2. **A61K 31/47 + A61K 2300/00**
3. **A61K 31/475 + A61K 2300/00**
4. **A61K 31/555 + A61K 2300/00**
5. **A61K 31/565 + A61K 2300/00**
6. **A61K 31/66 + A61K 2300/00**
7. **A61K 31/70 + A61K 2300/00**
8. **A61K 33/00 + A61K 2300/00**
9. **A61K 38/38 + A61K 2300/00**
10. **A61K 38/38 + A61K 31/66 + A61K 31/565 + A61K 31/70**
11. **A61K 38/38 + A61K 31/66 + A61K 31/565 + A61K 31/555**
12. **A61K 38/38 + A61K 31/66 + A61K 31/565 + A61K 31/475**
13. **A61K 38/38 + A61K 31/66 + A61K 31/565 + A61K 31/47**
14. **A61K 38/38 + A61K 31/66 + A61K 31/565 + A61K 31/40**
15. **A61K 38/38 + A61K 31/66 + A61K 31/565 + A61K 31/335**
16. **A61K 31/335 + A61K 2300/00**
17. **A61K 31/40 + A61K 2300/00**

Citation (search report)

See references of WO 0110446A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0110446 A2 20010215; WO 0110446 A3 20010525; AU 6280900 A 20010305; BR 0013276 A 20040803; CA 2380312 A1 20010215; CN 1511037 A 20040707; CZ 2002376 A3 20020612; EA 200200234 A1 20020627; EP 1206266 A2 20020522; HU P0202645 A2 20021228; HU P0202645 A3 20040628; IL 147745 A0 20020814; JP 2003506408 A 20030218; KR 20020019967 A 20020313; MX PA02001395 A 20020812; NO 20020631 D0 20020208; NO 20020631 L 20020208; NZ 517632 A 20040227; PL 353406 A1 20031117; SK 1782002 A3 20020509

DOCDB simple family (application)

EP 0007678 W 20000803; AU 6280900 A 20000803; BR 0013276 A 20000803; CA 2380312 A 20000803; CN 00811442 A 20000803; CZ 2002376 A 20000803; EA 200200234 A 20000803; EP 00949471 A 20000803; HU P0202645 A 20000803; IL 14774500 A 20000803; JP 2001514963 A 20000803; KR 20027001700 A 20020207; MX PA02001395 A 20000803; NO 20020631 A 20020208; NZ 51763200 A 20000803; PL 35340600 A 20000803; SK 1782002 A 20000803